Isabelle Havis1, Trinity Coates1, Kara J Wyant1, C Chauncey Spears1, Mark Garwood1, Vikas Kotagal1,2. 1. Department of Neurology, University of Michigan, Ann Arbor, Michigan. 2. Veterans Affairs Ann Arbor Healthcare System and Veterans Affairs Ann Arbor Healthcare System Geriatric Research Education and Clinical Center, Ann Arbor, Michigan.
Abstract
STUDY OBJECTIVE: Identifying individuals with isolated rapid eye movement sleep behavioral disorder (iRBD) is an important clinical research priority for future synucleinopathy trials. Nevertheless, little is known about the breadth of clinical settings where diagnoses of iRBD are initially made. METHODS: We conducted a retrospective cohort study using the electronic medical record system at the University of Michigan to identify patients aged ≥ 60 years with new diagnoses of iRBD between 2015 and 2020. We focused specifically on patients receiving primary care at the University of Michigan so that we might use the university's electronic medical record system to capture the full scope of their multispecialty care interactions and diagnoses in this integrated health care system. We used International Classification of Diseases, Ninth Revision and Tenth Revision, diagnosis codes to identify the time of initial clinical diagnosis. RESULTS: We found that 62/105 (59.0%) diagnoses were made by a sleep specialist, 9 (8.6%) by neurologists, and 30 (29.5%) by generalists or primary care (29.5%) providers. In addition, 67/105 (63.8%) diagnoses were made in the context of having available polysomnography results, while the remainder was made on the basis of clinical symptoms alone. The prognostic implications of iRBD were documented in 40/105 (38.1%) encounter notes and were more likely to occur in sleep clinic settings (chi-square = 12.74; P < .001) than in other contexts. CONCLUSIONS: Initial iRBD diagnoses occur in varied clinical settings in an integrated health care system and are often made without a confirmatory polysomnogram. Documented prognostic counseling is seen most often in sleep medicine clinics. Synucleinopathy prevention trials may be best designed around a sleep clinic-focused recruitment approach. CITATION: Havis I, Coates T, Wyant KJ, Spears CC, Garwood M, Kotagal V. Isolated REM sleep behavior disorder in North American older adults in an integrated health care system. J Clin Sleep Med. 2022;18(9):2173-2178.
STUDY OBJECTIVE: Identifying individuals with isolated rapid eye movement sleep behavioral disorder (iRBD) is an important clinical research priority for future synucleinopathy trials. Nevertheless, little is known about the breadth of clinical settings where diagnoses of iRBD are initially made. METHODS: We conducted a retrospective cohort study using the electronic medical record system at the University of Michigan to identify patients aged ≥ 60 years with new diagnoses of iRBD between 2015 and 2020. We focused specifically on patients receiving primary care at the University of Michigan so that we might use the university's electronic medical record system to capture the full scope of their multispecialty care interactions and diagnoses in this integrated health care system. We used International Classification of Diseases, Ninth Revision and Tenth Revision, diagnosis codes to identify the time of initial clinical diagnosis. RESULTS: We found that 62/105 (59.0%) diagnoses were made by a sleep specialist, 9 (8.6%) by neurologists, and 30 (29.5%) by generalists or primary care (29.5%) providers. In addition, 67/105 (63.8%) diagnoses were made in the context of having available polysomnography results, while the remainder was made on the basis of clinical symptoms alone. The prognostic implications of iRBD were documented in 40/105 (38.1%) encounter notes and were more likely to occur in sleep clinic settings (chi-square = 12.74; P < .001) than in other contexts. CONCLUSIONS: Initial iRBD diagnoses occur in varied clinical settings in an integrated health care system and are often made without a confirmatory polysomnogram. Documented prognostic counseling is seen most often in sleep medicine clinics. Synucleinopathy prevention trials may be best designed around a sleep clinic-focused recruitment approach. CITATION: Havis I, Coates T, Wyant KJ, Spears CC, Garwood M, Kotagal V. Isolated REM sleep behavior disorder in North American older adults in an integrated health care system. J Clin Sleep Med. 2022;18(9):2173-2178.
Authors: Louise Robinson; Alan Gemski; Clare Abley; John Bond; John Keady; Sarah Campbell; Kritika Samsi; Jill Manthorpe Journal: Int Psychogeriatr Date: 2011-02-01 Impact factor: 3.878
Authors: Birgit Frauscher; Viola Gschliesser; Elisabeth Brandauer; Isabelle Marti; Martin T Furtner; Hanno Ulmer; Werner Poewe; Birgit Högl Journal: Sleep Med Date: 2010-02 Impact factor: 3.492
Authors: Olaf P Geerse; Daniela J Lamas; Rachelle E Bernacki; Justin J Sanders; Joanna Paladino; Annette J Berendsen; Thijo J N Hiltermann; Charlotta Lindvall; Erik K Fromme; Susan D Block Journal: J Palliat Med Date: 2020-06-22 Impact factor: 2.947
Authors: Max A Feinstein; Richard R Sharp; David J Sandness; John C Feemster; Mithri Junna; Suresh Kotagal; Melissa C Lipford; Maja Tippmann-Peikert; Bradley F Boeve; Michael H Silber; Erik K St Louis Journal: Sleep Med Date: 2019-03-22 Impact factor: 3.492
Authors: Matteo Cesari; Anna Heidbreder; Erik K St Louis; Friederike Sixel-Döring; Donald L Bliwise; Luca Baldelli; Frederik Bes; Maria Livia Fantini; Alex Iranzo; Stine Knudsen-Heier; Geert Mayer; Stuart McCarter; Jiri Nepozitek; Milena Pavlova; Federica Provini; Joan Santamaria; Jun-Sang Sunwoo; Aleksandar Videnovic; Birgit Högl; Poul Jennum; Julie A E Christensen; Ambra Stefani Journal: Sleep Date: 2022-03-14 Impact factor: 5.849
Authors: Jennifer G Goldman; Leah K Forsberg; Bradley F Boeve; Melissa J Armstrong; David J Irwin; Tanis J Ferman; Doug Galasko; James E Galvin; Daniel Kaufer; James Leverenz; Carol F Lippa; Karen Marder; Victor Abler; Kevin Biglan; Michael Irizarry; Bill Keller; Leanne Munsie; Masaki Nakagawa; Angela Taylor; Todd Graham Journal: Alzheimers Res Ther Date: 2020-10-29 Impact factor: 6.982